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The value of psychological treatment for borderline personality disorder:
systematic review and cost offset analysis of economic evaluations
Abstract
Aim Borderline Personality Disorder (BPD) is a common mental health condition with high patterns of
service utilisation of inpatient and community treatment. Over the past five years there has been
significant growth in research with economic data, making this systematic review a timely update.
Methods Empirical studies written in English or German, published up to December 2015, and cited in
major electronic databases were examined using the PRISMA systematic review method. Papers were
included that had one of the following: data related to cost of BPD to society, the individual, the carer or
families; cost benefits of interventions. Reported cost data were inflated to the year 2015 and converted
into US- dollars (USD $) using purchasing power parities.
Results We identified 30 economic evaluations providing cost data related to interventions for BPD across
134,136 patients. The methodological quality was good, almost all studies fulfilled ≥ 50% of the quality
criteria. The mean cost saving for treating BPD with evidence-based psychotherapy across studies was
USD $2,987.82 per patient per year. A further mean weighted reduction of USD $1,551 per patient per year
(range $83 - $29,392) was found compared to treatment as usual. Evidence-based psychological
treatment was both less expensive as well as more effective, despite considerable differences in health
cost arrangements between individual studies and countries. Where it was able to be calculated, a
significant difference in cost-savings between different types of evidence-based psychotherapies was
found.
Discussion Individuals with BPD consistently demonstrate high patterns of service utilization and
therefore high costs. The findings of this review present a strong argument in favour of prioritizing BPD
treatments in reimbursement decisions, both for the affected individual and the family. The provision of
evidence based treatment, irrespective of the type of psychological treatment, may lead to widespread
reductions in healthcare costs.
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Aim
Borderline Personality Disorder (BPD) is a common mental health condition with high patterns of service utilisation of inpatient and community treatment. Over the past five years
there has been significant growth in research with economic data, making this systematic
review a timely update.

Methods
Empirical studies written in English or German, published up to December 2015, and cited
in major electronic databases were examined using the PRISMA systematic review method.
Papers were included that had one of the following: data related to cost of BPD to society,
the individual, the carer or families; cost benefits of interventions. Reported cost data were
inflated to the year 2015 and converted into US- dollars (USD $) using purchasing power
parities.

Results
We identified 30 economic evaluations providing cost data related to interventions for BPD
across 134,136 patients. The methodological quality was good, almost all studies fulfilled 
50% of the quality criteria. The mean cost saving for treating BPD with evidence-based
psychotherapy across studies was USD $2,987.82 per patient per year. A further mean
weighted reduction of USD $1,551 per patient per year (range $83 - $29,392) was found
compared to treatment as usual. Evidence-based psychological treatment was both less
expensive as well as more effective, despite considerable differences in health cost arrangements between individual studies and countries. Where it was able to be calculated, a
significant difference in cost-savings between different types of evidence-based psychotherapies was found.
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Discussion
Individuals with BPD consistently demonstrate high patterns of service utilization and therefore high costs. The findings of this review present a strong argument in favour of prioritizing
BPD treatments in reimbursement decisions, both for the affected individual and the family.
The provision of evidence based treatment, irrespective of the type of psychological treatment, may lead to widespread reductions in healthcare costs.

Introduction
In a budget constrained health care system, the cost and benefits of psychological interventions
are increasingly of interest as decisions regarding resource allocation have forced individuals
to re-examine the cost effectiveness of psychological treatments [1,2]. In particular clinicians
are increasingly faced with numerous challenges surrounding decisions regarding treatment
options which need to be both ethically informed and based on available research findings.
Concurrent with the debate on health care reform, and the relative dearth of evidence-based
treatment for Personality Disorders (PD), clinicians have become increasingly interested in
evaluating the cost-effectiveness of psychological treatments [3]. Attention to the cost-benefit
analysis is crucial in weighing the benefits versus disadvantages of specific interventions and
treatment approaches [4], clearly defining the method, duration and outcomes of interventions. Managed care providers demand that treatments have demonstrated efficacy, minimize
costs, and reduce future utilization of expensive resources.
Previous research in the field has highlighted that individuals suffering Borderline Personality Disorder (BPD) pose a high economic burden on society due to their extensive use of treatment services [5–7]. This is understandable as BPD is present in 1–2% of the population,
10% of psychiatric outpatients and between 15% and 25% of inpatients [8–10]. Additionally
patients with BPD present to services at a high risk of self-harm, with up to 10% of psychiatric
outpatients committing suicide, a rate almost 50 times higher than the general population
[11]. The widespread economic impacts of the condition is aggravated by the fact that individuals suffering BPD typically need several repeated treatments, including urgent interventions
in emergency departments and seek help repeatedly and simultaneously from multiple sources
[12,13].
Within mental health settings, Sansone and colleagues (2011) [6] found that patients
with BPD symptomology appear to have a significantly higher turnover with primary care physicians and see a greater number of specialists than patients without these symptoms. Additionally, Bender and colleagues (2001) [5] found that compared to individuals with major
depression, those with BPD were significantly more likely to use most types of psychiatric
treatment. Finally, in an Australian community sample, Jackson and Burgess (2004) [14]
found that individuals with BPD were more likely than other individuals to seek psychiatric or
psychological consultations. Given the seemingly consistent pattern of high utilization of mental health services among individuals with BPD, these findings may reflect the underlying psychological processes of the disorder as well as a general pattern of demand for healthcare
services [15].
Treatment guidelines for BPD support psychotherapy in the community as the treatment of
choice [16]. Studies of different psychological therapies such as mentalization based treatment,
transference focused therapy and dialectical behaviour therapy, have demonstrated positive
outcomes in relation to symptomology and levels of service use [9]. However, due to the nature
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of BPD symptoms, the identification of psychotherapies and utilisation of interventions that
are cost-effective with this population is of considerable importance. While many factors influence the likelihood that a treatment is effective, one of the primary factors has become the
affordability of treatment. That is, the pure monetary value one saves or loses by investing in
one treatment compared to another. Brazier and colleagues (2006) [17] completed a systematic
review and a preliminary economic evaluation of available therapies for BPD patients [17]. In
2014, Brettschneider and colleagues [18] performed a systematic literature review of 15 existing economic evaluations of treatments for BPD up to 2012, but the economic evaluations
reviewed used different comparators to define costs, which made comparability of the data difficult and the findings not sufficient to draw robust conclusions for all treatments. There has
been no updated review over the past 5 years despite a surge in economic data available.
Therefore the present study aims to systematically review and synthesize the literature on
this topic and provide an updated overview (i.e. up to December 2015). We are specifically
focused at looking at the cost-benefit of recognised evaluated treatments, as the results can be
used to gain insight into how much society is spending on BPD, and potentially how much can
be saved if effective therapy is offered. The information can be helpful in setting priorities for
health care efficiency research as high societal costs present a strong argument in favour of prioritizing BPD treatments in reimbursement decisions, in terms of health insurance benefits for
affected individuals and funding grants to provide accessible and effective treatment services.

Materials and methods
Protocol and registration
This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis
(PRISMA) Statement for Reporting Systematic Reviews [19] and additional guidelines for conducting and reporting systematic reviews [20]. The protocol was registered by the International Prospective Register of Systematic Reviews (registration number: CRD42016037305).

Data sources
Literature was searched for relevant articles published up to December 2015 using the following online databases: Psychological and Behavioural Sciences, PsychInfo, Scopus, Medline,
Web of Science and PubMed. Search terms used for each database included the following: Borderline Personality Disorder OR Personality Disorder AND cost OR cost analysis OR cost benefit OR cost effectiveness OR economic analysis OR (burden AND (society OR community
OR individual OR carer OR carers)). This search identified papers directly related to the
research questions.

Study selection
The eligibility of the studies was assessed in two steps. First titles and abstracts were screened.
Subsequently, articles considered as relevant were obtained and the full text was screened. All
original studies reporting cost or cost-effectiveness data of BPD were included.
Studies were eligible for further consideration in this review if they related to the costs or
benefits of interventions for BPD (specifically cost or benefit to the individual, carer or family,
or society either through direct (e.g. medical) or indirect (e.g. loss of productivity) costs or
benefits. Studies were excluded if they were not in English or German, or did not publish original empirical data (e.g. newspaper articles, reviews, commentaries and editorials). Records
identified by the searching process were screened by two authors (DM, AM) and checked by
another (BG).
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Data extraction and risk of bias
Two authors (DM and AM) extracted data from the included studies, which was then independently reviewed by another author (BG). This author was blind to prestige factors, including
authors, institutions, journal titles, and publishers. The authors compared their findings and
discrepancies were discussed and resolved to reach a consensus.
Data extracted included: country of publication, cost year, study sample characteristics (number of participants, age, gender, types of treatment compared), cost (per population and per
patient), and if stated, type of economic evaluation.
Two categories of costs can be distinguished: direct and indirect costs; [21,22]. Direct costs
include all treatment costs that arise directly from medical care. These include items such as
the cost of psychiatric inpatient and outpatient care, psychological, rehabilitation, medication,
or emergency room treatments. Indirect costs cover all costs that occur secondary to the disease. These include items such as production losses and sickness benefit payments due to days
absent at work, as well as years lost due to mortality. In addition, the total costs (either indirect
or direct) associated with the delivery of the intervention (intervention costs) were also
presented.
For the purpose of this review, type of economic evaluation [21], was described and defined
as follows:
1. Full economic evaluations. A full economic evaluation does not only compare costs of at
least two interventions but also their consequences (outcomes, effects) [21]. Effects can be
measured in natural units (life years gained, parasuicide events avoided, artificial units
(quality-adjusted life years [QALY] or disability-adjusted life years [DALY]) or monetary
units measured by techniques like willingness-to-pay experiments. Depending on the effect
measure employed, full economic evaluations are called cost-effectiveness analyses (natural
units), cost-utility analyses (utility measures) or cost-benefit analyses (outcomes valued
monetarily).
2. Partial economic evaluations. Health economic studies considered to be partial economic
evaluations do not make explicit comparisons between alternative interventions in terms of
both costs (resource use) and consequences (effects). In partial economic evaluations only the
costs of at least two alternatives are compared (i.e. cost analyses, cost-description studies and
cost-outcome descriptions). Partial evaluations can be useful in that they can provide elements of information for a full evaluation and help answer questions not related to efficiency.
Whilst the methodologies of full economic evaluations and partical economic evaluations
are distinct from each other, both types of economic evaluations were included for the purposes of our review. Debate exists as to whether the information derived from partial economic
evaluations are of the same scientific value and usefulness as the information derived by full
economic evaluations, nevertheless, including both types of economic evaluations will contribute useful evidence to an understanding of economic aspects of interventions.

Quality assessment
Quality assessment of the studies included was performed by means of the Consensus on
Health Economic Criteria (CHEC) checklist. The CHEC-list has been developed using a Delphi method (three Delphi rounds; 23 international experts). The CHEC-list comprehends 19
criteria formulated as a question for answering either by "yes" or "no" [23].
The results of the quality assessment are displayed as percentage of studies fulfilling each
criterion.
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Cost-offset analysis
The focus of this review is on costing issues associated with the provision of interventions for
the treatment of BPD, including costs, cost-effectiveness and cost offset (i.e., a reduction in
health care costs attributable to the intervention provided). Cost offsets originate from the use
of mental health services and related costs before, during and after (if applicable) a specific
intervention. Interventions included were recognised psychological treatments that have separately been shown to have clinical effectiveness and therefore an evidence-base [9].Therefore
data was extracted based on cost alone, without further consideration of clinical effectiveness
as this had been separately established and is outside the scope of this review.
Cost offset PT. The cost offset of psychotherapeutic interventions (PT) (Cost offset PT)
was calculated by subtracting the total costs after the intervention provided from the total costs
before the start of the intervention (i.e. pre-post differences in healthcare costs).
Cost offset PT vs. TAU. The cost offset of a psychotherapeutic intervention PT vs. TAU
(Cost offset PT vs. TAU) represents the difference in total costs after the intervention is provided compared to cost related to the provision of treatment as usual (TAU) (i.e. post- difference in healthcare cost related to PT vs. TAU).
In order to assess the costs and cost offsets, and to present a financial evaluation, we applied
present-day financial costing standards to the data. Cost data were inflated and converted to
2015 US-$ purchasing power parities (PPP) to ensure comparability of the data [24].
If an included study did not report the cost year, the year in which the study was accepted
for publication was used as a proxy. To further ensure comparability of the data, costs per
patient were calculated if costs data related to groups or a population. Subsequently, if the time
horizon chosen in the study was less or more than one year, costs were converted to one year
costs.
Due to the variation in sample size, means weighted for sample size were calculated and
reported when presenting the overall cost offset of PT and the overall cost offset of PT vs TAU
of all the economic evaluations identified in this review, and where appropriate, compared
using independent samples t test.

Results
Search results
The search of electronic databases resulted in the identification of 4660 studies (4380 with
duplicates removed). An additional 25 studies were identified through cross referencing and
consultation with experts, yielding 4405 potentially relevant articles.
Of these, 4220 were excluded as their titles and/or abstracts clearly indicated that they did
not meet the inclusion criteria.
Of the remaining 185 articles, 137 were excluded because primary focus was not BPD
(n = 39), the articles were a secondary review without original data (n = 12), or the articles contained no cost or benefit data (n = 86).
Full text screening was performed for the remaining 48 articles. 19 articles were excluded of
which 12 did not report on cost data, four were not mainly focused on BPD and three were
review articles; not containing original data. Finally, 29 articles (30 evaluations) were considered in this review (see Fig 1 for PRISMA Flowchart).

Characteristics of studies included
The characteristics of the included studies are summarized in Table 1.

PLOS ONE | DOI:10.1371/journal.pone.0171592 March 1, 2017

5 / 19

Cost offset of treatments for borderline personality disorder: A systematic review

Fig 1. PRISMA Flowchart for the selection of studies included in the systematic review.
doi:10.1371/journal.pone.0171592.g001

Of the total 30 evaluations (29 articles) considered in this review, 19 evaluations were full
evaluations and 11 evaluations were partial economic evaluations. Twelve evaluations were
conducted in the United Kingdom (UK), five in the United States of America, four each in the
Netherlands and in Australia, three in Germany and one each in Norway and Switzerland.
The majority of the evaluations employed the societal perspective. The time horizon of the
evaluations ranged from 12 weeks to nine years. Most evaluations included less than 100
patients (n = 24), some even less than 50 (n = 16). We included five economic evaluations with
a study population of n > 100 patients. The 30 evaluations bring the total number of patients
in this review to n = 134,136.
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Table 1. Summary of the cost differences in the economic evaluations reviewed (indirect/direct + intervention costs calculated for 2015, per
patient, time horizon as stated).
Study

Currency Study
Type

Sample
Size

Mean
age

Gender Time
Treatment
horizon

Amner, 2012 [28]

GBP

21

36.2

81% F

Bateman & Fonagy, USD
2003c [25]

Partial
Partial

41

31.8

58% F

1 year
3 years

DBT
MBT

pre

8,715

post

6,885

pre

2,633

post
TAU
Berrino et al. 2011c
[48]

CHF

Full

200

32.1

85% F

3
months

Borschmann et al.,
2013 [49]

GBP

Full

88

35.8

81% F

6
months

Brazier et al. 2006
[17] based on

GBP

Full

24

22

79% F

1 year

Turner et al. 2000c
[32]
Brazier et al. 2006
[17] based on

GBP

Full

44

N.A.

N.A.

1 year

on Linehan et al.
1991c [40]
Brazier et al. 2006
[17] based on

GBP

Full

58

37.5

100% F 1 year

van den Bosch et al.
2002c [41]
Brazier et al. 2006
[17] based on

GBP

Full

28

35

100% F 1 year

Koons et al. 2001c
[42]
Brazier et al. 2006
[17] based on

GBP

Full

38

31.8

58% F

1 year

Bateman et al.
1999c [47]
Brazier et al. 2006
[17] based on

GBP

Full

480

32

68% F

1 year

Tyrer et al. 2003c
[50]

Direct
Costsa

post

1,050

CI

post

11,775

TAU

post

14,773

CP

post

6,459

TAU

post

6,852

DBT

post

22,320

14,705

CCT

post

29,760

13,214

DBT

post

33,510

27,834

TAU

post

36,088

16,995

DBT

post

20,911

14,392

TAU

post

20,042

7,270

DBT

post

29,271

21,112

TAU

post

18,504

10,249

MBT

post

27,858

TAU

post

27,198

MACT

post

12,716

TAU

post

10,038

CBT-PD post

186
691

76

31.9

84% F

6 years

TAU

post

Goodman et al.,
2011c [27]

USD

Partial

233

51.32

95% F

1 year

N.A.

post

Grazia Turri &
Andreatta, 2014
[36]

GBP

Partial

1

N.A.

N.A.

9 years

LT-P

pre

Hall et al. 2001 [54]

AUD

Partial

30

29.4

63% F

1 year

CM

pre

31,340

post

8,974

post

637

post

44

N.A.

N.A.

1 year

1,599

DBT

Cost Cost
Offset Offset
PT b PT vs.
TAU b
1,829
811 283

187

Full

Full

8,670

3,564

GBP

USD

Intervention
Costsa

pre

Davidson et al.
2010c [51]

Heard, 2000 (study
one) [33]

Indirect
Costsa

2,100
11,988

178

786

7,432

2578

-869

-10,771

-661

-2677

84

17,3707
3,165

2,048

271

5,322

22,366

731

640
(Continued)
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Table 1. (Continued)
Study

Currency Study
Type

Sample
Size

Mean
age

Gender Time
Treatment
horizon

Heard, 2000 (study
two) [33]

USD

Full

38

N.A.

N.A.

1 year

Kvarstein et al.,
2013 [37]

EUR

Full

107

31

76% F

3 years

TAU

post

1,277

DBT

post

638

SCP

post

1,094

SDC

pre
post

pre

33,323

post

29,990

post
41

47.1

46% F

1,5 year DBT

Palmer et al., 2006
[26]

Full

106

31.9

84% F

2 years

CBT

TAU

2,389

586

1,953

11,713

8,453

3,333

398

pre

138

post

336

pre

215

post

501

DBT

post

24,920

AUD

Full

90

33.58

93% F

3 years

TAU

post

25,966

Perseius et al.,
2004 [30]

SEK

Partial

22

N.A.

N.A.

2,5
years

DBT

pre

11,0168

post

26,132

Prendergast &

AUD

Full

11

36.35

100% F 1 year

DBT

McCausland,2007
[44]

Cost Cost
Offset Offset
PT b PT vs.
TAU b
456

1,373

Pasieczny &
Connor, 2011 [43]

c

Intervention
Costsa

776

pre

Partial

Indirect
Costsa

825

OPC
Meyers et al., 2014c USD
[29]
GBP

Direct
Costsa

37

-99 83

2,092

10,073

56,024

post

11,603

TAU

Priebe et al., 2012
[45]

GBP

Full

80

32.2

100% F 1 year

DBT

post

173

34

Richter et al., 2014c
[46]

EUR

Full

31

33.3

94% F

12
weeks

TAU

post

114

31

DBT

post

Stevenson &
Meares, 1999 [34]

AUD

Partial

30

29.4

63% F

1 year

CM

pre

Van Asselt et al.
2007 [3]

EUR

Full

131900

30.5

92% F

1 year

N.A.

pre

10,081 10,850

Van Asselt et al.,
2008a [39]

EUR

Full

86

30.6

93% F

5 year

SFT

post

33,795 13,273

Van Asselt et al.,
2008b [38]

EUR

Partial

86

TFP

post

44,116 14,254

30.6

93% F

4 years

SFT

post

263d

TFP

post

278d

post

-61

29,392
25,676

14,633

24,122

1,554

Wagner et al., 2013
[53]

EUR

Partial

55

30.2

93% F

1 year

DBT

pre

22,397 11,096

Wagner et al., 2014
[31]

EUR

Partial

47

30.1

92% F

3 year

DBT

pre

505 238

post

174 217

2,825

4

497

352

(Continued)
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Table 1. (Continued)
Study

Currency Study
Type

Total
a

Sample
Size

Mean
age

Gender Time
Treatment
horizon

134136

30.56e 89% Fe

Direct
Costsa

Indirect
Costsa

Intervention
Costsa

Cost Cost
Offset Offset
PT b PT vs.
TAU b

Foreign currencies are converted to US dollars, per patient. Then costs were inflated to 2015 US dollars.

b

Cost offsets were calculated for 2015 US dollars costs, per patient, per year. PT = Psychotherapy; TAU = Treatment As Usual.

c

Cost year was not reported in the study, year of publication was used as proxy.
Average of calculated bootstrapped productivity costs according to the Friction Cost (FC) Method and the Human Capital (HC)- method (i.e. HC–limited

d

and HC -extended Method).
e

Weighted averages
Cost Offset PT = Difference in pre and post total (indirect + direct) costs for PT: Cost Offset PT vs. TAU = Difference in post total (indirect + direct) costs
for PT vs. TAU.
DBT: Dialectical Behaviour Therapy; CBT-PD: Cognitive-Behavioural Therapy for personality disorders, CBT: Cognitive Behavioral Therapy in addition to
TAU; CCT: Client Centered Therapy control condition; CI: Crisis Intervention at the General Hospital; CP: Joint Crisis Plan + Treatment As Usual; CM:
Conversational Model; LT-P: Long Term Psychoanalytic Psychotherapy; MACT: Manual-Assisted Cognitive Behavioural Therapy; MBT: Mentalization
Based Therapy; OPC: Outpatient Individual Psychotherapy; SCP: Stable Psychotherapy in Community; SDC: Individual and group therapy; SFT: SchemaFocused Therapy; TFP: Transference-Focused Therapy.
AUD: Australian Dollar; CHF: Swiss Franc; EUR: Euros; GBP: Pound Sterling; SEK: Swedish Krona; USD: United States Dollar.
N.A.: Not Available; F: female.
doi:10.1371/journal.pone.0171592.t001

In all evaluations the majority of patients were female; in most evaluations (n = 16) the proportion of female patients was larger than 80%. The overall weighted percent of female patients
across the studies included was 89%.
The mean age of populations ranged from 22 years to 51 years. The weighted average age
was 30.65 years across the 30 studies included.

Treatments compared
Regarding treatment comparisons, the studies generally fell into two following categories: 1)
studies that examine (one or two competing) psychotherapeutic interventions or 2) studies
examining psychotherapeutic interventions versus Treatment As Usual (TAU). A few studies
included both categories [25,26]. In addition to the pre-post analysis comparing cost pre- and
post intervention the study by Bateman & Fonagy (2003) [25] and the study by Palmer and colleagues (2006) [26] also examined the pre- and post- intervention costs in comparison to the
provision of TAU. In two evaluations [3,27], the examined intervention was clarified and no
comparison of treatments was made.
Studies comparing psychotherapeutic interventions. A total of fifteen evaluations examined the use of mental health services and related costs associated with the provision of a psychological treatment (i.e. other than TAU) in BPD patients.
Of these, seven focused on the costs solely related to the provision of DBT [28–33] Of latter
two studies DBT was compared to an alternative psychotherapeutic intervention [32,33].
Turner and colleagues (2000) [32] reported on a comparison of DBT with a client-centered
therapy control condition (CCT) whereas Heard and colleagues (2000) [33] conducted a comparison between a stable psychotherapy in community (SCP) and DBT.
Other psychotherapeutic interventions examined in these fifteen evaluations are: Conversational Model (CM) [34,35]; Long term psychoanalytic psychotherapy (LT-P) [36]; Kvarstein
and colleagues (2013) [37] provided the pre- and post- costs associated with Individual and
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group therapy giving in a step-down condition (SDC) and Outpatient Individual Psychotherapy (OPC). In two evaluations Schema Focused Therapy (SFT) and Transference Focused Psychotherapy (TFP) were the competing psychotherapeutic interventions [38,39]. Mentalization
Based Therapy (MBT) was examined in the study by Bateman & Fonagy (2003) [25] whereas
Palmer and colleagues (2006) [26] provided the cost associated with the provision of Cognitive
Behavioural Therapy (CBT) in addition to TAU. See Table 1.
Studies comparing psychotherapeutic interventions versus treatment as usual. Fifteen
evaluations studied a psychotherapeutic intervention against treatment as usual (TAU). Of
these, eight evaluated dialectical behaviour therapy (DBT) with TAU [33,40–46]. Two studies
evaluated Mentalization based therapy (MBT) with TAU [25,47]. The following psychotherapeutic interventions were investigated by one evaluation each, using TAU for comparison: Crisis intervention at the general hospital (CI) [48], Joint crisis plan plus treatment as usual (CP)
[49], manual assisted cognitive behavioural therapy (MACT) [50], Cognitive behavioural therapy for personality disorders (CBT-PD) [51] and Cognitive Behavioural Therapy (CBT) in
addition to TAU [26]. In all of these studies, TAU was considered as standard of care for all
patients and could involve a range of therapeutic options.
Methodological quality of identified studies. The results of the assessment of methodological quality are presented in Table 2. Each criteria of the quality assessment was fulfilled by
the majority of the studies ( 50% of the studies). Criteria 14 and criteria 19 were fulfilled by
12 (43%) of the 30 studies included. None of the included studies fulfilled all of the quality criteria (Table 2). However, in the context of this review, the description of model details and
cost data was suboptimal in most of the studies, with Pasciezny and Conner (2011) [43] being
the exception (8 quality criteria were fulfilled).

Cost categories
Most of the studies (n = 26) examined considered direct costs (see Table 1). These studies
reported a diverse range of direct costs: costs for inpatient (costs of general and psychiatric
hospital services) and outpatient treatment, rehabilitation, medication or emergency room
treatments were assessed by most evaluations.
Five of the studies in this review presented data on both direct and indirect costs
[3,31,45,52]. Indirect costs items included mortality, early retirement, sickness absence, production losses, work disability and reduced quality of life. One study [38] focussed exclusively
on indirect costs, no direct costs were examined.
Intervention related costs were reported by 16 studies (see Table 1: Intervention Costs)
Three studies included in this review did not report any data on direct or indirect cost
[27,44,46]. Goodman et al. (2011) [27] focused on the out-of-pocket expenses and insurance
costs directly related to the treatment of BPD (i.e. therefore categorised as intervention costs in
this review). In addition, Prendergast & McCausland (2007) [44] and Richter and colleagues
(2013) [46] did not provide the actual (in)direct costs for inpatient and/or outpatient treatment
in the paper, only cost-savings of providing DBT compared to TAU were provided (i.e. cost
offset PT vs. TAU).

Cost outcome approach
The majority of studies (18 evaluations) presented data on post- intervention costs only
[27,32,33,38–51]. Eleven studies presented data on healthcare costs before (pre) and after
(post) providing the intervention [26,28–31,34,36,37,44,53,54]. One study reported only on
pre-intervention costs [52]. See Table 1.
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Table 2. Economic studies meeting the criteria for methodological quality on the CHEC-list (Evers,
Goossens, de Vet, van Tulder, & Ament, 2005).
Criteria

Yes

Proportion of
studies fulfilled
criteria

1. Is the study population clearly described?

[3–25–26–27–28–29–30–31–33–34–
36–37–38–39–42–43–44–45–46–
47–48–49–50–51–53–54]

87%

2. Are competing alternatives clearly
described?

[3–25–26–27–28–29–30–31–32–33–
36–37–38–39–40–41–42–43–44–
45–46–47– 48–49–50–51–53–54]

97%

3. Is a well-defined research question posed
in answerable form?

[3–25–26–27–28–29–30–31–32–33–
36–37–38–39–40–41–42–43–44–
45–46–47– 48–49–50–51–53–54]

97%

4. Is the economic study design appropriate
to the stated objective?

[3–25–26–32–33–37–38–39–40–41–
42–44–45–46–47–49–50–51]

63%

5. Is the chosen time horizon appropriate in
order to include relevant costs and
consequences?

[3–25–26–27–28–29–30–31–32–33–
34–36–37–38–39–40–41–44–45–
47–48–49–50–51–53–54]

90%

6. Is the actual perspective chosen
appropriate?

[3–25–26–28–29–30–31–32–33–36–
37–38–39–40–41–42–43–47–49–
50–51–53–54]

80%

7. Are all important and relevant costs for
each alternative identified?

[3–25–26–27–28–29–30–31–33–34–
36–37–38–39–41–42–43–45–48–
49–51–53–54]

60%

8. Are all costs measured appropriately in
physical units?

[3–25–26–28–30–31–32–33–36–37–
38–39–40–41–42–43–45––47– 48–
49–50–51–53–54]

80%

9. Are costs valued appropriately?

[3–26–29–30–31–32–33–36–37–39–
46–47–50–53–54]

83%

10. Are all important and relevant outcomes
for each alternative identified?

[3–29–30–31–32–33–36–37–39–46–
47–50–53–54]

53%

11. Are all outcomes measured
appropriately?

[3–26–27–28–30–31–33–34–36–37–
39–40–41–42–45–46–50–53–54]

67%

12. Are outcomes valued appropriately?

[3–26–28–29–30–31–32–33–36–37–
39–40–41–42–45–46–47–50–53–54]

70%

13. Is an incremental analysis of costs and
outcomes of alternatives performed?

[3–26–29–32–37–39–40–41–42–45–
47–50–54]

43%

14. Are all future costs and outcomes
discounted appropriately?

[3–26–27–28–29–31–32–33–36–38–
39–40–41–42–43–45–47–48–49–
50–53–54]

76%

15. Are all important variables, whose values [27–28–33–36–37–38–39–40–41–
are uncertain, appropriately subjected to
42–47–49–50–54]
sensitivity analysis?

50%

16. Do the conclusions follow from the data
reported?

[3–25–26–27–28–29–30–31–32–33–
34–36–37–38–39–40–41–42–43–
44–45–46–47–48–49–50–51–53–54]

100%

17. Does the study discuss the
generalizability of the results to other
settings and patient/client groups?

[3–25–27–28–29–30–31–32–33–34–
36–37–38–40–41–42–44–45–46–
47–50–53–54]

80%

18. Does the article indicate that there is no
potential conflict of interest of study
researcher(s) and funder(s)?

[3–26–27–30–31–32–34–37–38–39–
40–41–42–44–45–46–47–49–50–
51–53–54]

73%

19. Are ethical and distributional issues
discussed appropriately?

[3–27–30–31–33–35–36–37–44–46–
53–54]

43%

doi:10.1371/journal.pone.0171592.t002
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Results of the economic evaluations
Primary analysis. The calculated cost offsets associated with the provision of (one or two
competing) psychotherapeutic interventions (PT) (i.e. Cost offset PT) and the additional costsavings of implementing evidence-based psychotherapy compared to TAU (i.e. Cost offset PT
vs. TAU) per patient per year, for each treatment approach separately, is shown in Table 1.
Three studies [3,27,52] only provided data on costs either before or after the intervention;
therefore no cost-savings comparison (i.e. cost- off set calculation) could be made. In addition,
we did not attempt to provide the overall cost savings of TAU. Only two studies included in
this review reported on pre- and post- cost data associated with the provision of TAU [25,26].
However, these findings are not sufficient to offset to any extent the cost-savings of the provision of TAU in the treatment of patients with BPD. Therefore TAU-related cost-data was not
reported.
Cost offset PT. All studies comparing cost pre- and post intervention (15 evaluations;
total sample size n = 787) reported a cost saving found to be in the range from USD $4 to
$56,024 per person/per year. The pre-post analysis resulted in a mean weighted cost-saving of
USD $5,840.92 [SD = $10,816.56; SE = $1,479.57] per patient per year (see Total Table 1 Cost
Offset PT). Only the study by Palmer and colleagues (2006) [26] reported an increase of $99 in
costs per patient/per year, post- intervention.
Because single group pre-post tests have recognised limitations, we have run additional
analysis without the non-controlled studies to overcome bias of our results. Seven non- controlled studies were identified as so [28–31,34,36,54] with a total sample size of n = 192. For
these non-controlled studies, the pre-post analysis resulted in a mean weighted cost-saving of
USD $14,682.56 [SD = $ 1,286.07; SE = $17,820.38] per patient per year.
Subsequenly, re-running our primary pre-post analysis of the costs of psychotherapeutic
interventions (cost offset PT) excluding the non-controlled studies yielded similar outcomes.
Without the inclusion of these seven non-controlled studies the overall weighted cost offset of
PT was: USD $2,987.82 [SD = $4390.31; SE = $180.01] per patient per year across these studies.
Cost offset PT vs. TAU. The 15 evaluations (total sample size n = 1,415) comparing the
healthcare costs of psychotherapeutic interventions for BPD to TAU related costs, mostly
reported cost-savings. See Table 1 Cost Offset PT vs. TAU. Compared to treatment as usual,
the additional weighted mean cost-savings of implementing evidence-based psychotherapy
was USD $1,551.37 per person per year [SD = $6,574.17; SE = $174.77]. These cost-savings
ranged from $83 to $29,392 per person/per year. Five evaluations [41,42,45,47,50] did not find
a cost-saving and reported an increase in costs when comparing healthcare costs of psychotherapeutic interventions for BPD to TAU related costs (increase in costs ranged from $61 to
$10,772). See Table 1.
Secondary analysis. We furthermore were interested in whether there were detectable differences in the cost-benefit of different types of psychological therapy. We were able to find six
studies of DBT and seven non-DBT alternative approaches. There are not enough studies to
directly compare two alternative approaches to date, we therefore pooled the seven non-DBT
studies. DBT was compared to TAU in six evaluations [33,40–43,45]. The (weighted) mean
cost-offset derived from the provision of DBT compared to TAU was USD $78.43 [SD =
$3,1412.83; SE = $184.01] per patient per year across these studies (total sample size n = 344).
Seven non-DBT evaluations focused on the post- healthcare costs related to the provision of
other psychological approaches, namely: MBT [25,47]; CI [48]; CP [49]; CBT-PD [51];
CBT-TAU [26] and MACT [50]. Compared to TAU, a (weighted) mean increase in costs of
USD -$1,150.03 [SD = $5,482.33; SE = $170.91] per patient per year was demonstrated across
the studies (total sample size n = 1029).
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The weighted mean difference in cost savings vs. TAU derived after the provision of
DBT vs. non-DBT studies was: $1,228.43 (SE = $251.13; 95% confidence interval $735.63 to
$1,721.30). This resulted in a significant weigthed mean difference (t(953.33.) = 4.892, p =
.000). Although the difference per patient is significant, it is important to recognise that treatments themselves begin from different cost bases–and DBT standard includes weekly 2.5
hours of group, one hour of individual and ancillary care and phone coaching–which is generally more intensive that the comparative treatments which are typically up to two hours individual per week. In addition, crisis care, because it diverts from hospitalisation, has a large
cost-offset. Although there are many potential interpretations for this significant finding, it
could suggest that there is a greater cost-benefit of non-DBT vs DBT approaches compared to
TAU. However, caution should be used when interpreting these results.

Discussion
Summary of main findings
This paper reviews data published in peer review journals on the economic evaluations of evidence-based treatments for BPD, to inform recommendations for current mental health care
funding policy. The results indicate that providing evidence-based treatments for BPD is costeffective and results in cost savings. Our 2015 US dollar cost-offset calculations indicated that
each individual in BPD treatment showed a reduction of USD $2,988 per patient per year in
total healthcare costs in the year following BPD treatment as compared to the year prior to
BPD. Perhaps more importantly, this review demonstrated that compared to treatment as
usual, that the provision of psychotherapy resulted in an additional cost-saving of USD $1,551
per patient per year.
Up to December 2015, thirty economic evaluations across 29 studies met the inclusion criteria of this review and provided valuable cost-data for calculating a cost-savings for the psychotherapies evaluated. Of the studies included in this review, fifteen evaluations examined the
economic benefits of a psychotherapeutic intervention using pre- and/or post-measures, but
without a control group. Another fifteen evaluations provided data on the use of mental health
services and related costs of psychotherapeutic intervention compared to treatment as usual
(TAU) or client centred therapy (CCT) as a control group. The costs data presented in three
evaluations [3,27,52] could not be used to calculate cost-savings. However, because our aim
was to include all original studies reporting cost or cost-effectiveness data of BPD and to reflect
the financial burden associated with BPD, these studies were included in the review and used
to maximise the available information about the economic value of the provision of psychological treatment of BPD. Examining the studies included, DBT was the most evaluated treatment
for BPD (15 evaluations). Other psychotherapeutic interventions examined by the studies included in this review were CM (2 evaluations), MBT (2 evaluations), SFT (2 evaluations) and
one each for CBT, CBT-PD CI, CP, LT-P, MACT, OPC, SCP, SDC and TFP, representing a variety of intervention approaches (see Table 2 for description of treatments). The mean cost-savings
derived from the provision DBT compared to TAU, did differ significantly from the additional
cost-savings as a result from other forms of psychotherapy (6 DBT vs. 7 non-DBT comparisons).
These findings could suggest that there is a greater cost-benefit of non-DBT vs DBT approaches
compared to TAU. However, this finding is exploratory in nature and should not be used to
draw firm conclusion about the cost savings of DBT or other forms of psychotherapy as there
are variations across studies in approach, setting, and context. Future studies should compare
costs of alternative treatments within the same project under similar conditions.
Our results suggest that psychotherapy for borderline personality disorders, independent of
the type of treatment, can lead to cost-savings. Comparison of the cost savings of DBT versus
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other forms of psychotherapies did not lead to a significant difference in cost reduction;
strengthening the status of the use of any form of well evaluated psychological therapy as the
main treatment of borderline personality disorders [9,55]. Our findings furthermore provide
evidence to support the assertion that offering effective therapy in BPD generates cost-saving
advantages in terms of both direct and indirect healthcare costs.

Strengths and limitations
Other reviews that have looked at economic evaluations [17,18,56], similarly found evidence
for cost-effective treatments for patients with BPD. To the best of our knowledge, there is no
recent study that estimated annual net cost-savings of providing treatment in patients with
BPD in a systematic way as conducted here. Brettschneider and colleagues (2014) [18] older
study reviewed 15 economic evaluations of psychological therapies for BPD, concluding that
the economic evidence is not sufficient to draw conclusions and current evidence should be
interpreted with caution due to methodological shortcomings. Our review updated this previous work and now includes 30 evaluations, providing firmer evidence for cost benefit.
Our estimates for cost benefit should be interpreted with caution as there was significant
variation between studies. However, as most studies included a control or active treatment
comparison, our estimates do reflect the entire evidence we were able to systematically review.
The key strength of our review is that it has used full resource-use data that have been
reported by researchers who have either conducted an economic evaluation of clinical trials or
reported healthcare costs associated with the provision of treatment for BPD. Moreover, the
focus of our review was not limited to specific psychological therapies and/or economic evaluations performed alongside clinical effectiveness randomized controlled trials. Hence, in this
review, adjustment of the cost-data to account for variation in the cost-methods used in the
different economic evaluations allowed comparison between treatments and enhanced generalizability of the study results.
However, this review was restricted to a certain extent by some limitations. We found that
among the economic evaluation studies there was a great heterogeneity in the definition of
costs, as have previous reviews [18]. Although we made a concerted effort to identify cost-categories, in some cases classifying the reported healthcare costs as either direct or indirect costs
was not clearly and based upon common-sense reasoning. Furthermore, the studies in this
review reported data from different countries, which could possible affect the generalisability
of study findings. There are differences in economic circumstances and in health systems
across various countries resulting in corresponding differences in health outcomes and their
costs. For example, the health service and societal perspective in the Netherlands is different
compared to the UK and Australian system. In the Australian, there is universal coverage for
health care services; with the federal government paying a large part of the cost of health services, whereas Health insurance in the Netherlands is mandatory and everyone has to take out
their own basic healthcare insurance [57]. Although we have made a considerable effort by calculating costs using purchasing power parity PPP, this should be taken into consideration
when interpreting the results.
Despite the demonstrated overall cost savings across the majority of the 30 evaluations
included, the cost-offset calculations for six economic evaluations included in this review
did not result in cost-savings [26,41,42,45,47,50]. In four of these [41,42,47,50] it may be that
the extra costs associated with the alternative therapy compared to the costs of the provision
of TAU may be due to the method of cost modelling in the studies [17,18]. In some cases,
resource use was estimated by authors by regression models [17], and for these economic evaluations costs may have been overestimated. Furthermore, the healthcare costs incurred before
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and after the provision of CBT [26] and after the provision of DBT [45] compared to TAU, did
not result in cost-savings. However, the cost differences in both studies were small and did not
approach conventional levels of statistical significance. In addition, it must be noted that the
intervention (CBT) examined by Palmer and colleagues (2006) [26] did result in an overall saving of USD $131 (per patient per year) in healthcare costs when compared with the provision
of TAU.
This systematic review aimed to provide an overview of the cost savings associated with the
provision of psychotherapeutic interventions for the treatment of BPD and was not intended
as a statement of the clinical effectiveness of these treatments. Data was extracted based on cost
alone, without further consideration of clinical effectiveness of these treatments and is outside
the scope of this review. However, the evidence on economic outcomesalone is one factor
informing clinical decision making in health care. Future studies may investigate the interaction between cost and clinical improvement, although this will rely upon an even larger pool
of studies of sufficient methodological rigour to allow such an evaluation.
Although we were able to identify thirty economic evaluations in total, a paucity of material
is apparent in this field, especially if we compare the modest number of economic findings
with the larger number of clinical evaluations. We have found some papers aiming to evaluate
the clinical and cost-effectiveness of evidence-based BPD treatment [58–60]. However, since
these papers only outline the background and methods of randomised controlled trials and are
still ongoing, these studies may inform future reviews.

Conclusions
Borderline Personality Disorder (BPD) is considered one of the most expensive mental disorders in terms of direct and indirect healthcare costs. Evidence-based treatment approaches for
BPD are available and demonstrate potential cost-saving when implemented effectively. This
review is the first to calculate the cost-savings associated with the provision of evidence-based
treatment for patients with BPD using all published data available for review. Evidence for
cost-effectiveness of psychological treatment was supported by our findings. Based on the findings of this systematic review, the provision of evidence-based psychological treatment to
patients with BPD results in a reduction in costs associated with both the use of mental health
services and related community costs, that significantly exceeds the cost of no treatment or
treatment as usual.
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